Literature DB >> 1319429

Pharmacology of benzodiazepine hypnotics.

D J Greenblatt1.   

Abstract

The "revolution" in pharmacologic treatment of insomnia began in 1970 with the availability of flurazepam, the first of the benzodiazepine hypnotics. Flurazepam largely replaced all other hypnotics during the decade of the 1970s. The second revolution began in the early 1980s as shorter half-life hypnotics, triazolam and temazepam, became available and began to replace flurazepam. The decade of the 1990s will probably see a more balanced pattern of benzodiazepine hypnotic use, as well as use of newer nonbenzodiazepine hypnotics. Among available benzodiazepines, all have the capacity to produce dose- and concentration-dependent sedation, drowsiness, performance impairment, and amnesia. Benzodiazepine-induced amnestic effects are characterized by either impairment of information acquisition, impairment of consolidation and storage, or both. In general, apparent clinical differences among benzodiazepine hypnotics are explained by differences in pharmacokinetic properties of absorption, distribution, elimination, and clearance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319429

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2014-07-29       Impact factor: 4.492

2.  Effects of a small dose of triazolam on P300 and resting EEG.

Authors:  J Urata; M Uchiyama; M Iyo; T Enomoto; T Hayakawa; M Tomiyama; T Nakajima; H Sasaki; S Shirakawa; K Wada; S Fukui; H Yamadera; M Okawa
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 3.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 4.  Clinically important drug interactions with intravenous anaesthetics in older patients.

Authors:  Helge Eilers; Claus Niemann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Modulation of human risky decision making by flunitrazepam.

Authors:  Scott D Lane; Don R Cherek; Sylvain O Nouvion
Journal:  Psychopharmacology (Berl)       Date:  2007-10-05       Impact factor: 4.530

6.  Benzodiazepine use and physical disability in community-dwelling older adults.

Authors:  Shelly L Gray; Andrea Z LaCroix; Joseph T Hanlon; Brenda W J H Penninx; David K Blough; Suzanne G Leveille; Margaret B Artz; Jack M Guralnik; Dave M Buchner
Journal:  J Am Geriatr Soc       Date:  2006-02       Impact factor: 5.562

Review 7.  Non-pharmacological treatments for insomnia.

Authors:  Matthew R Ebben; Arthur J Spielman
Journal:  J Behav Med       Date:  2009-01-24

8.  The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial.

Authors:  Robyn Tamblyn; Tewodros Eguale; David L Buckeridge; Allen Huang; James Hanley; Kristen Reidel; Sherry Shi; Nancy Winslade
Journal:  J Am Med Inform Assoc       Date:  2012-01-12       Impact factor: 4.497

9.  Neuronal network pharmacodynamics of GABAergic modulation in the human cortex determined using pharmaco-magnetoencephalography.

Authors:  Stephen D Hall; Gareth R Barnes; Paul L Furlong; Stefano Seri; Arjan Hillebrand
Journal:  Hum Brain Mapp       Date:  2010-04       Impact factor: 5.038

10.  Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance.

Authors:  Angela F Caveney; Bruno Giordani; George M Haig
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.